清胰降脂方联合腹部穴位敷贴治疗高脂血症性急性胰腺炎的疗效研究

doi:10.11958/20253179

天津医药 ›› 2026, Vol. 54 ›› Issue (4): 417-422.doi: 10.11958/20253179

清胰降脂方联合腹部穴位敷贴治疗高脂血症性急性胰腺炎的疗效研究

邝生(), 石方臻^△(), 张永亮

昆山市第六人民医院消化内科（邮编215321）

收稿日期:2025-10-17 修回日期:2025-11-17 出版日期:2026-04-15 发布日期:2026-04-14
通讯作者: ^△E-mail：19890125@qq.com
作者简介:邝生（1985），男，副主任中医师，主要从事中医内科脾胃病方面研究。E-mail：15062624069@163.com
基金资助:
昆山市高层次卫生人才计划人才科研项目(昆卫科教（2025）4号C-28)

Efficacy study of a self-formulated pancreatic-cleansing and lipid-lowering formula combined with abdominal acupoint plasters in the treatment of hyperlipidaemic acute pancreatitis

KUANG Sheng(), SHI Fangzhen^△(), ZHANG Yongliang

Department of Gastroenterology, Kunshan Sixth People's Hospital, Kunshan 215321, China

Received:2025-10-17 Revised:2025-11-17 Published:2026-04-15 Online:2026-04-14
Contact: ^△E-mail：19890125@qq.com

邝生, 石方臻, 张永亮. 清胰降脂方联合腹部穴位敷贴治疗高脂血症性急性胰腺炎的疗效研究[J]. 天津医药, 2026, 54(4): 417-422.

KUANG Sheng, SHI Fangzhen, ZHANG Yongliang. Efficacy study of a self-formulated pancreatic-cleansing and lipid-lowering formula combined with abdominal acupoint plasters in the treatment of hyperlipidaemic acute pancreatitis[J]. Tianjin Medical Journal, 2026, 54(4): 417-422.

摘要/Abstract

摘要：

目的探究自拟清胰降脂方联合腹部穴位敷贴治疗高脂血症性急性胰腺炎（HLAP）的临床疗效。方法选择2024年5月—2025年8月收治的70例HLAP患者作为研究对象，随机分为观察组和对照组，每组35例。对照组给予常规西医治疗，观察组在对照组的基础上给予自拟清胰降脂方联合穴位敷贴治疗，2组均治疗10 d。比较2组临床疗效及不良反应发生率。于治疗前、治疗3 d、治疗10 d时，检测患者淀粉酶、血脂及炎性因子水平，并行改良CT严重程度指数（MCTSI）评估。结果观察组临床总有效率显著高于对照组，差异有统计学意义（P<0.05）；重复测量方差分析结果显示，血清淀粉酶、尿淀粉酶、三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、血清C反应蛋白（CRP）、白细胞（WBC）水平及MCTSI评分在组间效应、时间效应与交互效应上差异均有统计学意义（P<0.05）。治疗3 d、10 d后，2组血清淀粉酶、尿淀粉酶、TG、TC、LDL-C、CRP、WBC及MCTSI评分均降低，HDL-C均升高，且观察组治疗3 d、10 d血清淀粉酶、尿淀粉酶、TG、TC、LDL-C、CRP、WBC及MCTSI评分低于对照组，HDL-C高于对照组（P<0.05）。2组不良反应发生率差异无统计学意义（P>0.05）。结论自拟清胰降脂方联合腹部穴位敷贴治疗HLAP可提高疗效，降低血脂水平，缓解炎症状态，加快症状改善，且不增加不良反应。

关键词: 胰腺炎, 高脂血症, 穴位贴敷疗法, 自拟清胰降脂方, 高脂血症性急性胰腺炎

Abstract:

Objective To investigate the clinical efficacy of a proprietary formula for clearing pancreas and lowering lipids combined with abdominal acupoint application in treating hyperlipidaemic acute pancreatitis (HLAP). Methods Seventy patients with HLAP admitted between May 2024 to August 2025 were selected as study subjects, and patients were randomly divided into the observation group (n=35) and the control group (n=35). The control group received conventional Western medical treatment, while the observation group received a proprietary formula for clearing pancreas and lowering lipids combined with acupoint plaster therapy on the basis of the control group. Both groups were treated for 10 days. The clinical efficacy and incidence of adverse reactions were compared between the two groups. The levels of amylase, blood lipids and inflammatory factors in patients of two groups were measured before treatment, 3 days after treatment and 10 days after treatment. The modified CT severity index (MCTSI) was used for evaluation. Results The clinical total effective rate was significantly higher in the observation group than that of the control group (P<0.05). The results of repeated measurement analysis showed that there were statistically significant differences in levels of serum amylase, urine amylase, triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), serum C-reactive protein (CRP), white blood cell (WBC) and MCTSI score in terms of inter group effects, time effects and interaction effects (P<0.05). After 3 days and 10 days of treatment, the scores of serum amylase, urine amylase, TG, TC, LDL-C, CRP, WBC and MCTSI were decreased in both groups, while HDL-C increased. Moreover, after 3 days and 10 days of treatment the scores of serum amylase, urine amylase, TG, TC, LDL-C, CRP, WBC and MCTSI were lower in the observation group than those of the control group (P<0.05), and HDL-C level was higher than that of the control group. There were no significant differences in adverse reactions between the two groups (P>0.05). Conclusion The combination of a proprietary formula for clearing pancreas and lowering lipids with abdominal acupoint plaster application in the treatment of hyperlipidaemic acute pancreatitis enhances therapeutic efficacy, reduces blood lipid levels, alleviates inflammatory states, regulates microcirculation, accelerates symptom improvement and demonstrates safety.

Key words: pancreatitis, hyperlipidemias, acupoint sticking therapy, proprietary formula for clearing the pancreas and lowering lipids, hyperlipidaemic acute pancreatitis

中图分类号:

R576.1

图/表 7

参考文献 19

[1]	程炯炯, 李琳琳, 赵浩东, 等. CRRT联合血浆置换救治高脂血症性重症急性胰腺炎患者的疗效分析[J]. 天津医药, 2023, 51(8):855-859.
	CHENG J J, LI L L, ZHAO H D, et al. Curative effect of CRRT combined with plasma exchange in the treatment of hyperlipidemic severe acute pancreatitis[J]. Tianjin Med J, 2023, 51(8):855-859. doi:10.11958/20221994.
[2]	杨敏, 仝高成, 邓蓉, 等. 乌司他丁联合生长抑素治疗高脂血症性急性胰腺炎患者的临床评价[J]. 中国药物应用与监测, 2025, 22(4):652-655.
	YANG M, TONG G C, DENG R, et al. Clinical efficacy of ulinastatin combined with somatostatin on treatment of patients with hyperlipidemia-induced acute pancreatitis[J]. Chin J Drug Appl Monit, 2025, 22(4):652-655.doi:10.3969/j.issn.1672-8157.2025.04.018.
[3]	杨建宇, 刘志军, 易苏红. 低分子肝素联合胰岛素治疗高脂血症性急性胰腺炎的临床效果[J]. 临床合理用药, 2025, 18(20):77-80.
	YANG J Y, LIU Z J, YI S H. Clinical effect of low molecular weight heparin combined with insulin in the treatment of hyperlipidemic acute pancreatitis[J]. Clin Rational Drug Use, 2025, 18(20):77-80. doi:10.15887/j.cnki.13-1389/r.2025.20.021.
[4]	杜学芳, 马尚超, 张利利, 等. 低分子肝素联合苯扎贝特治疗高脂血症性急性胰腺炎的效果[J]. 河南医学研究, 2024, 33(17):3215-3219.
	DU X F, MA S C, ZHANG L L, et al. Effect of low molecular weight heparin combined with benzabate in the treatment of hyperlipidemic acute pancreatitis[J]. Henan Med Res, 2024, 33(17):3215-3219. doi:10.3969/j.issn.1004-437X.2024.17.037.
[5]	卢振峰, 郭静生, 张爱萍, 等. 中药方剂治疗高脂血症急性胰腺炎临床疗效和安全性的系统评价与Meta分析[J]. 中医临床研究, 2023, 15(21):69-73.
	LU Z F, GUO J S, ZHANG A P, et al. Systematic evaluation and Meta-analysis of the clinical efficacy and safety of TCM prescription in the treatment of hypertriglyceridemia acute pancreatitis[J]. J Clin Chin Med, 2023, 15(21):69-73. doi:10.3969/j.issn.1674-7860.2023.21.013.
[6]	《高甘油三酯血症性急性胰腺炎诊治急诊专家共识》专家组. 高甘油三酯血症性急性胰腺炎诊治急诊专家共识[J]. 中国全科医学, 2021, 24(30):3781-3793.
	Expert group of emergency expert consensus on diagnosis and treatment of hypertriglyceridemic acute pancreatitis. Emergency expert consensus on diagnosis and treatment of hypertriglyceridemic acute pancreatitis[J]. Chinese General Practice, 2021, 24(30):3781-3793. doi:10.12114/j.issn.1007-9572.2021.02.028.
[7]	王宏, 安莹, 闫铁静, 等. 降脂消胰汤内服与灌肠联合西药治疗高脂血症性胰腺炎疗效及对患者血脂、凝血功能的影响[J]. 陕西中医, 2024, 45(6):785-788.
	WANG H, AN Y, YAN T J, et al. Effects of oral and enema administration of Jiangzhi Xiaoyi decoction combined with western medicine on blood lipid levels,coagulation function in patients with hyperlipidemic pancreatitis[J]. Shaanxi J Tradit Chin Med, 2024, 45(6):785-788. doi:10.3969/j.issn.1000-7369.2024.06.013.
[8]	王红, 王天麟, 梁磊, 等. 基于"脾不散精、浊毒内生"理论探讨从脾论治高甘油三酯血症性急性胰腺炎[J]. 中国中西医结合外科杂志, 2025, 31(2):165-169.
	WANG H, WANG T L, LIANG L, et al. Exploring the treatment of hypertriglyceridemic acute pancreatitis from the spleen based on the theory of "spleen failing to disperse essence and endogenous turbid toxin"[J]. Chin J Integr Tradit West Surg, 2025, 31(2):165-169. doi:10.3969/j.issn.1007-6948.2025.02.001.
[9]	张艳青, 郭安兵, 彭利军. 血脂康胶囊联合非诺贝特胶囊治疗高脂血症性胰腺炎的疗效观察[J]. 临床和实验医学杂志, 2023, 22(17):1809-1813.
	ZHANG Y Q, GUO A B, PENG L J. Observation on the therapeutic effect of Xuezhikang capsule combined with fenofibrate capsule on hyperlipidemic pancreatitis[J]. J Clin Exp Med, 2023, 22(17):1809-1813. doi:10.3969/j.issn.1671-4695.2023.17.005.
[10]	刘爽, 王垂杰. 从痰瘀理论探讨高脂血症性胰腺炎[J]. 环球中医药, 2019, 12(2):243-244.
	LIU S, WANG C J. Discussion on hyperlipidemic acute pancreatitis from the theory of phlegm and blood stasis[J]. Glob Tradit Chin Med, 2019, 12(2):243-244. doi:10.3969/j.issn.1674-1749.2019.02.025.
[11]	ZHENG C, ZHENG Y, ZHENG Z. Therapeutic plasma exchange decreases serum triglyceride level rapidly and reduces early recurrence rate but no advantages in improving outcomes for patients with hyperlipidemic acute pancreatitis:a retrospective propensity score matching analysis based on twenty year's experience[J]. BMC Endocr Disord, 2024, 24(1):32. doi:10.1186/s12902-024-01562-z.
[12]	QIN R, LIU Y, DING R, et al. Efficacy of double filtration plasmapheresis in hyperlipidemia acute pancreatitis:a retrospective observational study[J]. Lipids Health Dis, 2025, 24(1):27. doi:10.1186/s12944-025-02448-2.
[13]	赵慧佳, 吴东, 吴文铭. 高脂血症性胰腺炎研究进展[J]. 协和医学杂志, 2022, 13(4):637-643.
	ZHAO H J, WU D, WU W M. Research advances of hyperlipidemic pancreatitis[J]. J Peking Union Med Coll Hosp, 2022, 13(4):637-643. doi:10.12290/xhyxzz.2021-0760.
[14]	卓宝琴, 陈烁, 孙雅, 等. 大黄芒硝散外敷联合穴位贴敷治疗急性胰腺炎疗效观察及对血清淀粉酶、炎症因子水平的影响[J]. 新中医, 2024, 56(16):166-170.
	ZHUO B Q, CHEN S, SUN Y, et al. Observation on the efficacy of Dahuang Mangxiao Powder external application combined with acupoint application in the treatment of acute pancreatitis and its influence on serum amylase and inflammatory factor levels[J]. J New Chin Med, 2024, 56(16):166-170. doi:10.13457/j.cnki.jncm.2024.16.032.
[15]	WANG X, CAI H, CHEN Z, et al. Baicalein alleviates pyroptosis and inflammation in hyperlipidemic pancreatitis by inhibiting NLRP3/Caspase-1 pathway through the miR-192-5p/TXNIP axis[J]. Int Immunopharmacol, 2021, 101(Pt B):108315. doi:10.1016/j.intimp.2021.108315.
[16]	GUO W X, LU X G, ZHAN L B, et al. Chinese herbal medicine therapy for hyperlipidemic acute pancreatitis:a systematic review and meta-analysis of randomized controlled trials[J]. Eur Rev Med Pharmacol Sci, 2023, 27(6):2256-2276. doi:10.26355/eurrev_202303_31760.
[17]	王桂春, 孔晔宏, 张雪乔, 等. 大承气汤保留灌肠联合足三里穴按摩在促进重症急性胰腺炎胃肠动力中的应用[J]. 中国中西医结合急救杂志, 2022, 29(2):183-186.
	WANG G C, KONG Y H, ZHANG X Q, et al. Application of Dachengqi Decoction retention enema combined with Zusanli acupoint massage in promoting gastrointestinal motility in severe acute pancreatitis[J]. Chin J Integr Tradit West Med Emerg Crit Care, 2022, 29(2):183-186. doi:10.3969/j.issn.1008-9691.2022.02.012.
[18]	肖雄, 李姝, 范涛, 等. 大柴胡汤治疗急性胰腺炎的效果观察[J]. 保健医学研究与实践, 2025, 22(5):115-120.
	XIAO X, LI S, FAN T, et al. Clinical observation on the efficacy of Dachaihu decoction in treating acute pancreatitis[J]. Health Med Res Pract, 2025, 22(5):115-120. doi:10.11986/j.issn.1673-873X.2025.05.19.
[19]	刘春霞, 贾秀贤, 王利峰, 等. 穴位贴敷联合芩栀清胰饮治疗急性胰腺炎的疗效观察及对胃肠功能的影响[J]. 上海针灸杂志, 2022, 41(7):656-660.
	LIU C X, JIA X X, WANG L F, et al. Efficacy observation of acupoint sticking therapy combined with Qin Zhi Qing Yi Yin for acute pancreatitis and its effect on gastrointestinal function[J]. Shanghai J Acupunct Moxibustion, 2022, 41(7):656-660. doi:10.13460/j.issn.1005-0957.2022.07.0656.

组别	年龄/岁	性别（男/女）	体质量指数/（kg/m²）	发病至入院时间/h
对照组	43.57±5.11	18/17	24.55±1.26	10.40±3.80
观察组	42.22±5.01	20/15	24.24±1.58	11.48±4.31
t或χ²	1.109	0.230	0.921	1.119

组别	年龄/岁	性别（男/女）	体质量指数/（kg/m²）	发病至入院时间/h
对照组	43.57±5.11	18/17	24.55±1.26	10.40±3.80
观察组	42.22±5.01	20/15	24.24±1.58	11.48±4.31
t或χ²	1.109	0.230	0.921	1.119

组别	显效	有效	无效	总有效
对照组	15（42.86）	13（37.14）	7（20.00）	28（80.00）
观察组	19（54.28）	15（42.86）	1（2.85）	34（97.14）
χ²				5.081^＊＊

组别	显效	有效	无效	总有效
对照组	15（42.86）	13（37.14）	7（20.00）	28（80.00）
观察组	19（54.28）	15（42.86）	1（2.85）	34（97.14）
χ²				5.081^＊＊

组别		血清淀粉酶
组别		治疗前	治疗3 d		治疗10 d
对照组		652.31±58.40	424.40±42.09^a		146.28±34.14^ab
观察组		647.62±57.43	382.11±37.12^a		120.37±25.61^ab
t		0.338	4.457^＊＊		3.592^＊＊
F_组间/F_时间/F_交互		15.700^＊＊/2 417.363^＊＊/3.217^＊
组别	尿淀粉酶
组别	治疗前			治疗3 d		治疗10 d
对照组	2 864.66±156.36			1 238.54±78.27^a		398.42±42.15^ab
观察组	2 889.62±161.35			1 089.51±75.40^a		304.43±36.07^ab
t	0.658			8.113^＊＊		10.040^＊＊
F_组间/F_时间/F_交互	25.995^＊＊/10 871.029^＊＊/8.711^＊＊

清胰降脂方联合腹部穴位敷贴治疗高脂血症性急性胰腺炎的疗效研究

Efficacy study of a self-formulated pancreatic-cleansing and lipid-lowering formula combined with abdominal acupoint plasters in the treatment of hyperlipidaemic acute pancreatitis

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 7

参考文献 19

相关文章 15

编辑推荐

Metrics

本文评价

组别	治疗前	治疗3 d	治疗10 d
对照组	6.80±1.61	5.17±1.15^a	3.17±1.04^ab
观察组	6.71±1.70	3.74±0.98^a	2.57±0.70^ab
t	0.216	5.592^＊＊	2.829^＊＊
F_组间/F_时间/F_交互	13.808^＊＊/162.073^＊＊/6.043^＊＊

组别	皮肤过敏	腹泻	恶心呕吐	头痛	出血	总发生
对照组	0（0.00）	2（5.71）	1（2.86）	2（5.71）	1（2.86）	6（17.14）
观察组	2（5.71）	1（2.86）	1（2.86）	1（2.86）	0（0.00）	5（14.29）
χ²						0.108

[1]	楚兴, 刘磊, 杨华, 陈宏. 胆总管结石并发急性胆源性胰腺炎的危险因素及预测模型的构建[J]. 天津医药, 2026, 54(1): 35-40.
[2]	陈慧, 赵凯, 刘振国, 常瑛, 巨康璐. 金丝桃素通过调控NLRP3炎症小体改善小鼠急性胰腺炎的机制探讨[J]. 天津医药, 2025, 53(8): 820-825.
[3]	董丹, 陈立娟, 俞荷花. 急性胰腺炎并发低血压的危险因素分析及预测模型建立[J]. 天津医药, 2025, 53(5): 509-513.
[4]	丁杨娟, 夏时海, 许威, 高庆红, 刘涛涛. 氧化应激及抗氧化剂在急性胰腺炎中的研究进展[J]. 天津医药, 2025, 53(4): 444-448.
[5]	范慧娟, 刘涛涛, 李楠, 夏时海. 间充质干细胞治疗急性胰腺炎的机制及研究进展[J]. 天津医药, 2025, 53(3): 331-336.
[6]	徐永, 孙杰, 胡宗举. 重症急性胰腺炎并发急性非结石性胆囊炎的影响因素分析及预测模型构建[J]. 天津医药, 2025, 53(12): 1270-1275.
[7]	张易, 俞荷花, 徐天鹏. 老年重症急性胰腺炎患者继发凝血功能障碍影响因素分析及预测模型建立[J]. 天津医药, 2025, 53(11): 1180-1185.
[8]	叶朝阳, 马建中, 李后俊, 魏鲲鹏. 急性胰腺炎患者外周血TLR4、IL-1β、NLR水平与疾病进展和预后的关系[J]. 天津医药, 2024, 52(6): 648-652.
[9]	王伟, 夏铭, 张玲, 郭庆红. 十二指肠镜下胆总管取石术后发生胰腺炎的影响因素分析[J]. 天津医药, 2024, 52(12): 1305-1308.
[10]	梁耀冰, 符振华, 赵梓粤, 罗剑明, 程冬瑀, 姜海行, 覃山羽. 高甘油三酯血症性急性胰腺炎并发急性呼吸衰竭危险因素及预测模型的建立[J]. 天津医药, 2024, 52(11): 1183-1187.
[11]	张桂贤, 刘大卫, 李文畅, 蔡隽, 宗文辉, 刘洪斌, 赵秀梅. BOC2抑制N-甲酰肽/甲酰肽受体信号通路减轻SAP炎症损伤的机制研究[J]. 天津医药, 2024, 52(10): 1031-1037.
[12]	杨文珊, 盛玉, 陈秀利, 陈吉. 小儿急性胰腺炎序贯化营养支持与肠外营养支持的疗效比较[J]. 天津医药, 2024, 52(10): 1061-1064.
[13]	程炯炯, 李琳琳, 赵浩东, 胡志旭, 陈卫东, 王兴宇. CRRT联合血浆置换救治高脂血症性重症急性胰腺炎患者的疗效分析[J]. 天津医药, 2023, 51(8): 855-859.
[14]	王小红, 钱晶, 王加伟, 祁小鸣, 孟芸, 王萍, 程睿智, 周国雄. 红景天苷辅助治疗中重症急性胰腺炎的机制研究[J]. 天津医药, 2023, 51(7): 762-765.
[15]	曾家月, 马昕玥, 马凤雨, 陈霞. 尿石素A通过TLR4/NF-κB信号通路对重症急性胰腺炎的保护作用及机制[J]. 天津医药, 2023, 51(6): 613-617.

组别	TG							TC
组别	治疗前			治疗3 d		治疗10 d		治疗前	治疗3 d			治疗10 d
对照组	13.28±2.52			9.02±1.83^a		5.15±1.22^ab		9.85±2.23	6.54±1.68^a			4.77±1.20^ab
观察组	14.10±2.79			6.58±1.60^a		3.42±1.04^ab		9.96±2.39	5.22±1.09^a			4.10±1.13^ab
t	1.145			5.932^＊＊		6.382^＊＊		0.202	3.900^＊＊			2.385^＊
F_组间/F_时间/F_交互	15.795^＊＊/392.634^＊＊/10.031^＊＊							5.424^＊/182.634^＊＊/3.206^＊
组别		LDL-C					HDL-C
组别		治疗前	治疗3 d		治疗10 d		治疗前			治疗3 d	治疗10 d
对照组		3.68±0.92	2.96±0.82^a		2.29±0.82^ab		0.94±0.12			1.23±0.15^a	1.40±0.19^ab
观察组		3.70±1.06	2.44±0.75^a		1.92±0.72^ab		0.93±0.15			1.44±0.22^a	1.72±0.28^ab
t		0.097	2.774^＊＊		2.240^＊		0.718			4.833^＊＊	5.682^＊＊
F_组间/F_时间/F_交互		9.616^＊＊/85.129^＊＊/3.734^＊					46.994^＊＊/225.620^＊＊/16.138^＊＊

组别	TG							TC
组别	治疗前			治疗3 d		治疗10 d		治疗前	治疗3 d			治疗10 d
对照组	13.28±2.52			9.02±1.83^a		5.15±1.22^ab		9.85±2.23	6.54±1.68^a			4.77±1.20^ab
观察组	14.10±2.79			6.58±1.60^a		3.42±1.04^ab		9.96±2.39	5.22±1.09^a			4.10±1.13^ab
t	1.145			5.932^＊＊		6.382^＊＊		0.202	3.900^＊＊			2.385^＊
F_组间/F_时间/F_交互	15.795^＊＊/392.634^＊＊/10.031^＊＊							5.424^＊/182.634^＊＊/3.206^＊
组别		LDL-C					HDL-C
组别		治疗前	治疗3 d		治疗10 d		治疗前			治疗3 d	治疗10 d
对照组		3.68±0.92	2.96±0.82^a		2.29±0.82^ab		0.94±0.12			1.23±0.15^a	1.40±0.19^ab
观察组		3.70±1.06	2.44±0.75^a		1.92±0.72^ab		0.93±0.15			1.44±0.22^a	1.72±0.28^ab
t		0.097	2.774^＊＊		2.240^＊		0.718			4.833^＊＊	5.682^＊＊
F_组间/F_时间/F_交互		9.616^＊＊/85.129^＊＊/3.734^＊					46.994^＊＊/225.620^＊＊/16.138^＊＊

组别	CRP/（mg/L）			WBC/（×10⁹/L）
组别	治疗前	治疗3 d	治疗10 d	治疗前	治疗3 d	治疗10 d
对照组	15.20±4.38	8.43±3.60^a	6.42±2.12^ab	86.35±11.52	56.24±8.31^a	26.35±4.90^ab
观察组	15.46±4.58	6.14±1.53^a	4.56±1.54^ab	88.41±10.88	50.22±7.46^a	20.14±4.12^ab
t	0.240	3.921^＊＊	7.512^＊＊	0.767	3.190^＊＊	5.741^＊＊
F_组间/F_时间/F_交互	13.059^＊＊/188.197^＊＊/3.673^＊			7.153^＊＊/1 475.369^＊＊/4.575^＊

组别	CRP/（mg/L）			WBC/（×10⁹/L）
组别	治疗前	治疗3 d	治疗10 d	治疗前	治疗3 d	治疗10 d
对照组	15.20±4.38	8.43±3.60^a	6.42±2.12^ab	86.35±11.52	56.24±8.31^a	26.35±4.90^ab
观察组	15.46±4.58	6.14±1.53^a	4.56±1.54^ab	88.41±10.88	50.22±7.46^a	20.14±4.12^ab
t	0.240	3.921^＊＊	7.512^＊＊	0.767	3.190^＊＊	5.741^＊＊
F_组间/F_时间/F_交互	13.059^＊＊/188.197^＊＊/3.673^＊			7.153^＊＊/1 475.369^＊＊/4.575^＊